266 related articles for article (PubMed ID: 19866469)
21. Osteoblasts produce soluble factors that induce a gene expression pattern in non-metastatic prostate cancer cells, similar to that found in bone metastatic prostate cancer cells.
Fu Z; Dozmorov IM; Keller ET
Prostate; 2002 Apr; 51(1):10-20. PubMed ID: 11920953
[TBL] [Abstract][Full Text] [Related]
22. Osteolytic prostate cancer cells induce the expression of specific cytokines in bone-forming osteoblasts through a Stat3/5-dependent mechanism.
Schulze J; Albers J; Baranowsky A; Keller J; Spiro A; Streichert T; Zustin J; Amling M; Schinke T
Bone; 2010 Feb; 46(2):524-33. PubMed ID: 19796718
[TBL] [Abstract][Full Text] [Related]
23. Osteoblast-secreted WISP-1 promotes adherence of prostate cancer cells to bone via the VCAM-1/integrin α4β1 system.
Chang AC; Chen PC; Lin YF; Su CM; Liu JF; Lin TH; Chuang SM; Tang CH
Cancer Lett; 2018 Jul; 426():47-56. PubMed ID: 29627497
[TBL] [Abstract][Full Text] [Related]
24. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone.
Lee Y; Schwarz E; Davies M; Jo M; Gates J; Wu J; Zhang X; Lieberman JR
J Orthop Res; 2003 Jan; 21(1):62-72. PubMed ID: 12507581
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
[TBL] [Abstract][Full Text] [Related]
26. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone.
Li ZG; Yang J; Vazquez ES; Rose D; Vakar-Lopez F; Mathew P; Lopez A; Logothetis CJ; Lin SH; Navone NM
Oncogene; 2008 Jan; 27(5):596-603. PubMed ID: 17700537
[TBL] [Abstract][Full Text] [Related]
27. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone.
Lu Y; Chen Q; Corey E; Xie W; Fan J; Mizokami A; Zhang J
Clin Exp Metastasis; 2009; 26(2):161-9. PubMed ID: 19002595
[TBL] [Abstract][Full Text] [Related]
28. p65-Dependent production of interleukin-1β by osteolytic prostate cancer cells causes an induction of chemokine expression in osteoblasts.
Schulze J; Weber K; Baranowsky A; Streichert T; Lange T; Spiro AS; Albers J; Seitz S; Zustin J; Amling M; Fehse B; Schinke T
Cancer Lett; 2012 Apr; 317(1):106-13. PubMed ID: 22108531
[TBL] [Abstract][Full Text] [Related]
29. Notch3 promotes prostate cancer-induced bone lesion development via MMP-3.
Ganguly SS; Hostetter G; Tang L; Frank SB; Saboda K; Mehra R; Wang L; Li X; Keller ET; Miranti CK
Oncogene; 2020 Jan; 39(1):204-218. PubMed ID: 31467432
[TBL] [Abstract][Full Text] [Related]
30. Protease-activated receptor-2 dependent and independent responses of bone cells to prostate cancer cell secretory products.
Pagel CN; Kularathna PK; Sanaei R; Young ND; Hooper JD; Mackie EJ
Prostate; 2022 May; 82(6):723-739. PubMed ID: 35167724
[TBL] [Abstract][Full Text] [Related]
31. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis.
Park HR; Min SK; Cho HD; Kim DH; Shin HS; Park YE
J Korean Med Sci; 2003 Aug; 18(4):541-6. PubMed ID: 12923331
[TBL] [Abstract][Full Text] [Related]
32. Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis.
Rubin J; Chung LW; Fan X; Zhu L; Murphy TC; Nanes MS; Rosen CJ
Prostate; 2004 Jan; 58(1):41-9. PubMed ID: 14673951
[TBL] [Abstract][Full Text] [Related]
33. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.
Guise TA; Mohammad KS; Clines G; Stebbins EG; Wong DH; Higgins LS; Vessella R; Corey E; Padalecki S; Suva L; Chirgwin JM
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6213s-6216s. PubMed ID: 17062703
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
Keller ET; Brown J
J Cell Biochem; 2004 Mar; 91(4):718-29. PubMed ID: 14991763
[TBL] [Abstract][Full Text] [Related]
36. Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis.
Elshafae SM; Dirksen WP; Alasonyalilar-Demirer A; Breitbach J; Yuan S; Kantake N; Supsavhad W; Hassan BB; Attia Z; Alstadt LB; Rosol TJ
Prostate; 2020 Jun; 80(9):698-714. PubMed ID: 32348616
[TBL] [Abstract][Full Text] [Related]
37. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
Dai J; Keller J; Zhang J; Lu Y; Yao Z; Keller ET
Cancer Res; 2005 Sep; 65(18):8274-85. PubMed ID: 16166304
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
[TBL] [Abstract][Full Text] [Related]
39. Direct inhibitory and indirect stimulatory effects of RAGE ligand S100 on sRANKL-induced osteoclastogenesis.
Yoshida T; Flegler A; Kozlov A; Stern PH
J Cell Biochem; 2009 Aug; 107(5):917-25. PubMed ID: 19415676
[TBL] [Abstract][Full Text] [Related]
40. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein.
Dai J; Kitagawa Y; Zhang J; Yao Z; Mizokami A; Cheng S; Nör J; McCauley LK; Taichman RS; Keller ET
Cancer Res; 2004 Feb; 64(3):994-9. PubMed ID: 14871830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]